[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"frailty\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:frailty":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,196,0,25,[9,48,69,96,124,184,217,247,271,297,345,372,399,429,460,482,511,537,560,586,615,639,658,685,708],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644894","sage-heart--senior-assessment-fragility-and-post-operative-qalys-1-year-after-emergency-heart-surgery-for-patients-aged-75-and-older-100644894",false,"NCT07677319","SAGE-Heart : Senior Assessment fraGility and Post-opErative QALYs 1 Year After Emergency HEART Surgery for Patients Aged 75 and Older","SAGE-Heart","Inclusion Criteria:\n\n* Patients aged ≥ 75 years who are affiliated with or beneficiaries of a social security scheme and undergoing emergency cardiac surgery under cardiopulmonary bypass, either immediate or urgent (relative) :\n\n  * Immediate emergency surgery: intervention performed before the start of the next working day following the decision to operate,\n  * Urgent (relative) emergency surgery: patients not admitted electively for surgery but requiring an intervention during the current hospital stay for medical reasons, and who cannot be discharged without undergoing a definitive procedure\n\nExclusion Criteria:\n\n* Patients requiring preoperative cardiopulmonary resuscitation\n* Scheduled (elective) surgery\n* Lack of informed consent\n* Impaired consciousness at the time of inclusion (defined by a Glasgow Coma Scale score \\\u003C 15)\n* Individuals under legal guardianship or judicial protection\n* Individuals participating in another interventional research protocol","ALL","75 Years",{"count":20,"type":21},265,"ESTIMATED","INTERVENTIONAL",[24],"NA","The hypothesis is that the preoperative Clinical Frailty Score (CFS) is a predictive factor for a loss in quality-adjusted life years (QALYs) one year after emergency cardiac surgery under cardiopulmonary bypass (CPB) in patients aged 75 years and older.",[27,28,29],"Frailty","Cardiac Surgery","QALYs",[27,31,28,32,29,33,34],"Elderly","Cardio-pulmonary Bypass","Clinical Frailty Scale","EuroQol, postoperative","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2025-12-03",{"date":43,"type":21},"2028-12-03",{"name":45,"class":46},"University Hospital, Bordeaux","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":47},"100514366","perioperative-prehabilitation-on-markers-of-fitness-and-frailty-in-patients-undergoing-elective-surgery-100514366","NCT05977556","Perioperative Prehabilitation on Markers of Fitness and Frailty in Patients Undergoing Elective Surgery","The Effect of Perioperative Prehabilitation on Markers of Fitness and Frailty in Patients Undergoing Elective Surgery: a Pilot, Pragmatic, Randomized Controlled Trial","Inclusion Criteria:\n\n* 50 years of age or older\n* score of 4-6 (vulnerable, mildly or moderately frail) on the clinical frailty scale (CFS)\n* scheduled for elective surgery\n* ambulatory (indoor and\u002For outdoor) with or without gait aids\n\nExclusion Criteria:\n\n* Unstable medical conditions that limit exercise tolerance such as ME\u002FCFS","50 Years",{"count":57,"type":21},50,[24],"A growing body of evidence suggests that patients who receive good perioperative care (i.e. care prior to surgery, during surgery, and after surgery) tend to have fewer complications, quicker recovery times, and shorter hospital stays. A key component of good perioperative care is recognizing individuals who have diminished physiological reserves (i.e. those who are vulnerable or frail). The stress of an invasive procedure can exhaust the diminished reserves of patients who are frail, which can in turn lead to perioperative complications, mortality and an increase burden to the healthcare system.\n\nEarly interventions in patients with diminished reserves can be applied to reduce the risk of complications and poor outcomes. There are emerging studies that show promising benefits of perioperative interventions, such as prehabilitation, though with some mixed findings. Exercise has been shown to reverse or modify the molecular driving factors of frailty, which involve dysregulation of cytokine and endocrine pathways.\n\nPhysical inactivity and prolonged sedentary behaviors are also emerging concerns in frailty because of the implicated deleterious health effects. Sedentary behaviors are associated with prevalence and severity of frailty. Among pre-frail and frail inactive adults, sedentary time is associated with higher mortality. Increasing physical activity is recommended as the most feasible approach to prevent and treat frailty. The aim of this study is to determine if a prehabilitation intervention that combines neuromuscular strength training and intervention to reduce sedentary behavior reduces complications, length of stay, and patient recovery, thereby also reducing the burden on the healthcare system.",[27],{"date":62,"type":39},"2026-07-01",{"date":64,"type":21},"2026-07",{"date":66,"type":21},"2028-06",{"name":68,"class":46},"University of Alberta",{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":47},"100433358","impact-of-auditory-stimulation-in-eating-pleasure-edere-2021-100433358","NCT04923087","Impact of Auditory Stimulation in Eating Pleasure (EDERE 2021)","Impact of Auditory Stimulation in Eating Pleasure : Multicentric Study With Biscuits With Crunchy Texture vs Soft Texture in 100 Seniors Affected or at Risk of Presbyacusis","EDERE 2021","Inclusion Criteria:\n\nSubjects 65 years of age or older, hospitalized in geriatrics or EHPAD residents.\n\nExclusion Criteria:\n\nrisk of false route when eating cookies, allergy to an ingredient in cookies",true,"65 Years",{"count":80,"type":21},100,"OBSERVATIONAL","Background. Decreased taste and smell contribute to loss of appetite (anorexia), and the resulting protein-energy malnutrition increases the frailty of the elderly. The risk of falls, disability, infections and depression often requires them to be institutionalized. Elderly, undernourished and toothless patients often complain about the monotony of a soft, mixed-texture diet. In a previous study, some participants highlighted the pleasure of crunching cookies that have a solid texture that can be eaten in any dental condition. However, the age-related decrease in hearing (presbyacusis) is frequent and progressive from the age of 60. The hypothesis of this work is that older patients may perceive a crunchy food crunching in their mouth, despite presbycusis. If the hypothesis is verified, this would make geriatric caregivers aware of the possibility of diversifying the texture of food, in order to stimulate the pleasure of eating and increase the dietary intake in this population of patients who are often undernourished, dysphagic, edentulous and hearing impaired. The originality of this study is to share the expertise of geriatricians and specialists in mastication\u002Fswallowing (dental surgeon, speech-language pathologist), hearing (ENT doctor, hearing care professional) and nutrition (dietician).\n\nType of study. Type of study MR-004 \"Research not involving the human person\". Protocol. Compare the noise and pleasure of crunching between two hyperprotein nutritional supplements: a soft filled cookie (Nutra Cake™, Délical, France) and a crunchy cookie of the Breton type (Protibis™, Solidages, France). Blind study impossible: each subject will eat a cookie then the other in a random order and will be his own control. The tests will be performed without the possible hearing aids, but with or without the dentures according to the patient's preference. Indeed, some patients have dental prostheses that are no longer suitable for chewing, and that they wear only for aesthetics. Objective. Validate the evaluation criteria \"Do you hear the biscuit crunch?\" and \"Is it a pleasure?\" If so, encourage diversification with crunchy foods with a suitable texture, as well as dental and prosthetic rehabilitation of dependent elderly people.",[27,84,85,86,87],"Malnutrition","Anorexia","Presbycusis","Edentulism Nos","2026-06-25",{"date":36,"type":39},{"date":91,"type":39},"2021-06-01",{"date":93,"type":21},"2027-06-25",{"name":95,"class":46},"Centre Hospitalier Universitaire de Nice",{"id":97,"slug":98,"hasResults":12,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":103,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100645032","can-serum-lumican-level-identify-a-hidden-fragility-phenotype-beyond-bone-mineral-density-in-postmenopausal-women-100645032","NCT07677072","Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?","LUMINOS","Inclusion Criteria:\n\nInclusion Criteria:\n\n* Female sex\n* Age 45 years or older\n* Postmenopausal status\n* Attendance at the Physical Medicine and Rehabilitation outpatient clinic\n* Undergoing routine bone mineral density (DEXA) assessment and osteoporosis laboratory evaluation\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\nExclusion Criteria:\n\n* Premenopausal women\n* Secondary causes of osteoporosis (e.g., malignancy, advanced renal failure, severe liver disease, significant endocrine disorders)\n* Active infection or acute inflammatory disease\n* Major surgery within the previous 6 months\n* Neurological or muscular disorders that may significantly affect muscle function\n* Inability to comply with study procedures and assessments\n* Current treatment with medications that significantly affect bone metabolism, including bisphosphonates, denosumab, teriparatide, or other anti-osteoporotic agents\n* Refusal or inability to provide written informed consent","FEMALE","45 Years",{"count":106,"type":21},98,"Osteoporosis is a major cause of morbidity and fragility fractures in postmenopausal women. Bone mineral density (BMD) alone may not fully reflect fracture risk and skeletal fragility. Lumican, an extracellular matrix proteoglycan involved in collagen organization and musculoskeletal tissue homeostasis, has emerged as a potential biomarker for bone health. This prospective observational study aims to investigate the relationship between serum lumican levels, bone mineral density, muscle strength, and clinical fragility indicators in postmenopausal women. Approximately 100 participants will undergo routine osteoporosis assessment including DEXA, laboratory testing, FRAX evaluation, and handgrip strength measurement. The study will evaluate whether serum lumican levels can identify a hidden fragility phenotype beyond conventional bone mineral density measurements.",[109,110,27,111],"Osteoporosis","Postmenopausal Osteoporosis","Fragility Fractures",[113,109,114,115],"Lumican","Fragility","FRAX","2026-06-24",{"date":38,"type":39},{"date":119,"type":39},"2026-05-15",{"date":121,"type":21},"2026-12-01",{"name":123,"class":46},"Kanuni Sultan Suleyman Training and Research Hospital",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":77,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":136,"conditions":137,"keywords":152,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":47},"100643981","health-ahead-comparative-effectiveness-study-100643981","NCT07669168","Health Ahead Comparative Effectiveness Study","Health Ahead: Sequential Comparative-Effectiveness Studies Toward Automated, Universally Deployable Preventive Health Screening","HACE","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up.\n\nExclusion Criteria:\n\n\\- Age under 18 years.","18 Years",{"count":134,"type":21},1000000,[24],"The Health Ahead Comparative Effectiveness Study is a pragmatic, parallel-arm interventional platform that systematically compares successive changes to preventive health screening - each isolated as a single variable against current practice - on the path toward a fully automated screening system deployable in any environment, including the most isolated and resource-limited communities. Each comparison is evaluated with a common set of engagement, behavior-change, experience, cost, and longitudinal outcome measures, allowing results to accumulate on a consistent yardstick across the life of the platform.\n\nThe first comparison evaluates static versus interactive personalized health report delivery. Subsequent pre-planned comparisons, added by protocol amendment, evaluate mobile community versus fixed laboratory screening; and a hybrid medical-droid plus human-delivery model versus human-only screening. All participants are simultaneously enrolled in the 100-Year Human Aging Study and the Human Observatory Study, contributing individual longitudinal and population-level causal inference data through those protocols.",[138,139,140,141,142,143,144,145,146,147,27,148,149,150,151],"Health Services Accessibility","Rural Health","Medically Underserved Area","Preventive Health Services","Patient Participation","Health Behavior","Aging","Cardiovascular Diseases","Metabolic Syndrome","Cognitive Dysfunction","Activities of Daily Living","Health Related Quality of Life","Health Equity","Telemedecine",[153,154,155,156,157,150,139,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174],"Sequential Platform Trial","Interactive Health Report","Health Activation","Mobile Health Screening","Comparative Effectiveness","Medically Underserved","Preventive Medicine","Patient Engagement","Cardiopulmonary Exercise Testing","Body Composition","DEXA","Health Ahead Bus","Mobile Clinic","Automated Screening","Medical Droids","Biological Age","Healthspan","Longevity","Life Expectancy","Chronic Disease","Cost-Effectiveness","Health Services Research","2026-06-20",{"date":88,"type":39},{"date":178,"type":21},"2026-06-09",{"date":180,"type":21},"2099-12-31",{"name":182,"class":183},"William Brandenburg, MD","INDUSTRY",{"id":185,"slug":186,"hasResults":12,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":192,"targetDuration":4,"studyType":22,"phases":194,"briefSummary":195,"conditions":196,"keywords":201,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":47},"100644394","the-shape-project-hospital-system-for-physical-activity-and-active-participation-after-hospitalized-decompensation-of-respiratory-chronic-diseases-100644394","NCT07663955","The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Diseases","The SHAPE Project (Hospital System for Physical Activity and Active Participation) After Hospitalized Decompensation of Respiratory Chronic Disease in Respiratory Patients","SHAPE","Inclusion Criteria:\n\n* Age 65 years or older\n* Admission at risk of functional decline (hospital admission lasting \\> 5 days) Discharge destination: Home or residence where the patient lived prior to admission\n* Favorable multidisciplinary assessment by the healthcare team responsible for the patient during admission regarding the patient's physical fitness to perform the SHAPE program\n\nExclusion Criteria:\n\n* Explicit decision by the patient not to participate\n* Musculoskeletal problem that limits mobility\n* Limiting sociopathy (socio-family environment not optimal to guarantee program adherence)\n* Drug dependence (condition at discharge not optimal to guarantee program adherence)\n* Insufficient digital literacy and\u002For lack of online resources that do not guarantee participation in telematic sessions\n* Discharge destination: Long-term convalescent care center\n* Advanced and\u002For terminal stage of lung disease (patients with the following resources activated: Home Care and Support Teams Program for advanced disease (PADES), intensive home care at discharge due to extreme frailty (AT-DOM), advanced chronic disease requiring palliative care and a life expectancy of 12 months or less (MACA))Unstable underlying non-pulmonary disease (whether medical or mental, for example: acute myocardial infarction) Recent myocardial infarction (MI), recent stroke, recent hospitalization for psychiatric decompensation\\*) \\*Recent = within the last 3 months\n* Unstable underlying pulmonary disease (vital hemoptysis, new thoracic neoplasm, high-intermediate risk pulmonary thromboembolism)",{"count":193,"type":21},90,[24],"It is widely established that a lack of adapted physical activity (APA) and sedentary behaviors increase the prevalence of frailty, which exacerbates chronic diseases. Hospital stays amplify this phenomenon, leading to physical deconditioning, often irreparable, especially in older patients if it is not detected and treated promptly. To date, there is no standard of care focused on APA to address frailty acquired during hospital stays. In this context, the SHAPE project (Hospital System for Physical Activity and Active Participation) aims to prevent dependency in older adults with chronic diseases by developing an innovative patient journey based on APA. The project seeks to reduce frailty acquired during hospital stays by establishing standards for APA prescription, based on early diagnosis and intervention. SHAPE ensures equal access to care through an accessible and user-friendly web platform, designed for older users and also including those in rural areas. It fosters the resilience of healthcare systems by integrating a preventive and multidisciplinary approach into hospital treatments and optimizes resources through a tiered care model that provides progressive and personalized care.\n\nAlthough hospital stays have been shown to trigger physical deconditioning, there is no adapted physical activity program initiated by the hospital and followed at home after hospital discharge from a severe exacerbation in patients with chronic respiratory diseases. The SHAPE Project offers a highly beneficial tool for patients with acute or exacerbated chronic respiratory disease requiring hospitalization, promoting better overall recovery after discharge. Furthermore, this project will foster healthy lifestyles and promote health from a sustainability and prevention perspective. Of particular interest is the opportunity to offer a lifestyle change program (physical activity and hygiene-dietary measures) focused on respiratory patients and adapted to their specific needs. Moreover, the project is considered innovative in implementing healthy clinical practices through telemedicine. In addition, it offers post-hospital discharge services that, to date, have not been considered in a generic way for respiratory patients except in selective subgroups (post-COVID, patients included in lung transplant program, etc.).\n\nIn respiratory patients who have required high-risk admission due to decompensation, the implementation of the SHAPE program after hospital discharge as a support program that combines an adapted physical activity plan and general hygiene and dietary advice will improve the health indicators (frailty, sarcopenia, dyspnea, exercise tolerance, quality of life) of these patients.",[27,197,198,199,200],"Sarcopenia","Hospital Discharge","Physical Activity","Acute Exacerbation Chronic Pulmonary Disease",[202,203,204,205,206],"adapted physical activity","frailty","sarcopenia","hospital discharge","acute exacerbation chronic pulmonary disease","NOT_YET_RECRUITING","2026-06-17",{"date":210,"type":39},"2026-06-23",{"date":212,"type":21},"2026-09-01",{"date":214,"type":21},"2028-03-30",{"name":216,"class":46},"Hospital Universitari de Bellvitge",{"id":218,"slug":219,"hasResults":12,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":17,"minAge":224,"maxAge":4,"enrollmentInfo":225,"targetDuration":4,"studyType":22,"phases":227,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":47},"100547207","a-partnered-evaluation-to-improve-the-identification-and-management-of-functional-impairment-and-frailty-among-older-veterans-in-primary-care-settings-100547207","NCT06404970","A Partnered Evaluation to Improve the Identification and Management of Functional Impairment and Frailty Among Older Veterans in Primary Care Settings","A Partnered Evaluation to Improve Identification and Management of Functional Impairment and Frailty for Older Veterans in VA Primary Care","Inclusion Criteria:\n\n* Veteran\n* \\>60 years old\n* Seen in Veterans Health Administration primary care after implementation begins\n\nExclusion Criteria:\n\n* Non-Veteran\n* \\\u003C60 years old\n* Not seen in Veterans Health Administration primary care","60 Years",{"count":226,"type":21},10000,[24],"Maintaining functional status, or the ability to perform daily activities, is central to older adults' quality of life, health, and ability to remain independent. Identifying functional impairments is essential for clinicians to provide optimal care to older adults, and on a population level, understanding function can help anticipate service needs. Yet uptake of standardized measurement of functional status into patient care has been slow and inconsistent due to the burden posed by current tools. The purpose of the proposed QUERI Partnered Evaluation Initiative is to implement and evaluate a patient-centered, low-burden intervention to improve measurement of functional status in VA primary care settings nationally. The investigators hypothesize that implementing this intervention will increase identification and improve management of functional impairment among older Veterans while providing key data to inform VHA strategic planning related to long-term services and supports.",[230,27],"Functional Impairment",[232,233,234,235,203,236],"adult, aged","adult, middle aged","primary health care","functional status","patient reported outcome measures","2026-06-16",{"date":239,"type":39},"2026-06-18",{"date":241,"type":39},"2025-03-03",{"date":243,"type":21},"2026-12-31",{"name":245,"class":246},"VA Office of Research and Development","FED",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":47},"100628570","preoperative-oral-nutrition-and-outcomes-in-frail-elderly-patients-with-femur-fractures-100628570","NCT07463352","Preoperative Oral Nutrition And Outcomes In Frail Elderly Patients With Femur Fractures","Evaluation of the Effects of Preoperative Oral Nutritional Support on Hemodynamic Stability, Morbidity, Mortality, and Anthropometric Measurements in Patients With Femur Fractures and High Frailty Index: A Prospective Observational Study","Inclusion Criteria:\n\n* Patients aged 65 years or older hospitalized with a diagnosis of femur fracture\n* High frailty index (Clinical Frailty Scale ≥ 5)\n* Patients expected to require postoperative intensive care\n\nExclusion Criteria:\n\n* Patients requiring preoperative intensive care\n* Patients unable to tolerate enteral nutrition\n* Patients with advanced liver or kidney failure\n* Patients unable to cooperate\n* Patients with neuromuscular disease\n* Patients with severe malnutrition according to NRS-2002 guidelines\n* Patients who refuse to participate",{"count":255,"type":21},228,"The goal of this observational study is to learn whether preoperative oral nutrition support improves clinical outcomes in elderly patients with femur fractures who have a high frailty index. The main questions it aims to answer are:\n\n* Does preoperative nutrition support improve hemodynamic stability during and after surgery?\n* Does it reduce postoperative complications, mortality, and length of hospital stay?\n\nResearchers will compare patients who receive preoperative oral nutrition support with those who follow routine nutrition.\n\nParticipants will:\n\n* Receive routine medical care with or without nutrition support\n* Have their hemodynamic values, complications, and outcomes recorded during hospitalization\n* Be followed at 30 and 90 days after surgery for complications and mortality.",[258,27,84],"Femoral Fractures",[260,261,27,84,262],"Hip Fractures","Geriatric Patients","Hemodynamic Stability","2026-06-15",{"date":237,"type":39},{"date":266,"type":39},"2026-03-12",{"date":268,"type":21},"2027-01-01",{"name":270,"class":46},"Duzce University",{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":279,"briefSummary":280,"conditions":281,"keywords":282,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":47},"100642824","nurse-led-telehealth-frailty-management-in-older-adults-100642824","NCT07634406","Nurse-Led Telehealth Frailty Management in Older Adults","The Effect of a Nurse-Led Telehealth-Supported Multicomponent Frailty Management Program on Frailty and Functional Status in Older Adults Living at Home: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 65 years or older\n* Living at home and not receiving institutional care\n* Frail or at risk of frailty\n* Having sufficient hearing and cognitive ability to communicate by telephone\n* Able to read, understand, and communicate in Turkish\n* Providing written informed consent\n\nExclusion Criteria:\n\n* Having advanced cognitive impairment such as dementia\n* Having hearing or speech problems that prevent communication\n* Being bedridden\n* Being in the terminal stage of illness\n* Participating in another intervention or education program at the same time\n* Having a serious physical or psychiatric condition that may prevent regular participation in the intervention",{"count":80,"type":21},[24],"Frailty is an important geriatric syndrome associated with reduced physiological reserve, functional decline, falls, hospitalization, and increased health care use among older adults. This randomized controlled trial aims to evaluate the effect of a nurse-led telehealth-supported multicomponent frailty management program on frailty level and functional status in older adults living at home.\n\nThe study will be conducted as a single-center, two-arm, parallel-group randomized controlled trial. A total of 100 older adults aged 65 years and older who are living at home and are frail or at risk of frailty will be randomly assigned to either the intervention group or the control group in a 1:1 ratio.\n\nParticipants in the intervention group will receive an 6-week nurse-led telehealth-supported frailty management program, including weekly telephone counseling and individualized follow-up. Participants in the control group will continue usual care. Data will be collected at baseline, at 6 weeks, and at 18 weeks. The primary outcome is frailty level measured using the FRAIL Scale. Secondary outcomes include functional status, depressive symptoms, number of falls, emergency department visits, and hospitalizations.",[27],[283,284,285,286,287,288],"Older adults","Telehealth","Nursing intervention","Frailty management","Functional status","Home care","2026-06-12",{"date":237,"type":39},{"date":292,"type":21},"2026-06-05",{"date":294,"type":21},"2026-10-15",{"name":296,"class":46},"Kutahya Health Sciences University",{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":77,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":306,"conditions":307,"keywords":318,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":343,"locationsCount":47},"100641995","human-observatory-study-100641995","NCT07646782","Human Observatory Study","The Human Observatory: A Prospective Individual and Population-Level Study of Aging, Health, and Longevity","HOS","Inclusion Criteria:\n\n* Enrolled in the 100-Year Human Aging Study at any fixed or mobile clinical site; OR completion of online health screener with provision of geographic anchor data and consent.\n\nExclusion Criteria:\n\n* Age under 18 years (current protocol; pediatric amendment planned).",{"count":134,"type":21},"The Human Observatory Study is a prospective observational and ecological surveillance study building a continuously-updating world model for human health, disease, and death at the individual and population level. Individual multi-system clinical data from enrolled participants are linked to a continuously-ingested ecological data infrastructure spanning environmental exposures, social determinants, genealogical and family history records, mortality data, and population health databases at geographic resolutions from home address to global scale and beyond. The resulting model generates individual screening recommendations informed by population-level causal estimates, and population-level causal forecasts anchored by present-timepoint individual clinical biology. Thus creating a feedback architecture designed to improve both simultaneously.",[144,308,309,171,145,310,147,146,27,311,312,313,148,149,314,315,316,150,317],"Mortality","All-cause Mortality","Neoplasms","Musculoskeletal Disease","Neurodegenerative Disease","Dementia","Disability Physical","Environmental Exposure","Occupational Diseases","Social Determinants of Health",[319,320,321,322,323,324,325,326,327,328,329,330,331,150,332,333,161,162,159,169,334,335,336,337,338],"longevity","biological aging","causal inference","life expectancy","exposome","Environmental Health","Social Determinants","Genealogy","Family History","Human Family Tree","Population Health","Neighborhood Health","Geographic Health Disparities","Mortality Prediction","Biomarker Validation","Functional Decline","Centenarian","Space Medicine","Aerospace Medicine","World Model",{"date":263,"type":39},{"date":341,"type":39},"2026-04-25",{"date":180,"type":21},{"name":344,"class":183},"Longevity Metrics, Inc.",{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":77,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":352,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":353,"conditions":354,"keywords":360,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":371,"locationsCount":47},"100636291","100-year-human-aging-study-100636291","NCT07563777","100-Year Human Aging Study","100-Year Human Aging Study: Prospective Longitudinal Validation of Multi-System Health Measurements Against Mortality and Aging Outcomes","Inclusion Criteria:\n\n* Age 18 years or older\n* Willing and able to provide written informed consent, or enrollment with consent of a legally authorized representative\n* Willing to participate in longitudinal follow-up\n\nExclusion Criteria:\n\n* Age under 18 years",{"count":134,"type":21},"The 100-Year Human Aging Study is a prospective, pragmatic, observational trial enrolling participants across fixed and mobile clinical sites to undergo comprehensive multi-system health screening and longitudinal follow-up until death. Participants are followed to determine whether measurements taken at enrollment and repeated across the lifespan - individually and in combination - predict all-cause mortality, cause-specific mortality, incident serious disease, and functional disability. The study is designed to generate the surrogate endpoint validation data that longevity medicine currently lacks.",[144,355,356,308,146,145,147,357,310,27,148,358,314,359,313],"Aging Well","All-Cause Mortality","Musculoskeletal Diseases","Health-Related Quality of Life","Neuro-Degenerative Disease",[170,161,162,159,361,332,334,169,171,362,363,364,333,365,329,335],"Surrogate Endpoint Validation","Biological Aging","Preventive Screening","Longitudinal Cohort","Human Performance",{"date":367,"type":39},"2026-06-11",{"date":369,"type":39},"2025-02-09",{"date":180,"type":21},{"name":344,"class":183},{"id":373,"slug":374,"hasResults":12,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":380,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":382,"conditions":383,"keywords":386,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":47},"100643067","easix-score-and-post-induction-hypotension-in-frail-patients-undergoing-non-cardiac-surgery-100643067","NCT07642765","EASIX Score and Post-Induction Hypotension in Frail Patients Undergoing Non-Cardiac Surgery","Evaluation of the Relationship Between Endothelial Activation and Stress Index (EASIX) and Post-Induction Hypotension in Frail Patients Undergoing Non-Cardiac Surgery: A Prospective Observational Cohort Study","PIXEL","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for elective non-cardiac surgery under general anesthesia\n* Clinical Frailty Scale (CFS) score of 4 or above\n* Available routine preoperative laboratory values (LDH, creatinine, platelet count) within 24 hours before surgery\n\nExclusion Criteria:\n\n* Cardiac surgery\n* Emergency surgery\n* Preoperative vasopressor infusion\n* Severe hematological disease\n* Missing laboratory data required for EASIX calculation",{"count":381,"type":21},160,"Post-induction hypotension (PIH) is a common and clinically significant hemodynamic complication following general anesthesia induction. Frail patients are particularly vulnerable due to impaired vascular reactivity and endothelial dysfunction. The Endothelial Activation and Stress Index (EASIX), calculated from routine laboratory parameters (LDH, creatinine, and platelet count), may serve as a preoperative biomarker to identify patients at risk for PIH.\n\nThis prospective observational cohort study aims to evaluate the association between preoperative EASIX score and the occurrence of post-induction hypotension in frail patients undergoing elective non-cardiac surgery under general anesthesia. A total of 160 patients with a Clinical Frailty Scale (CFS) score of 4 or above will be enrolled. Mean arterial pressure will be measured every 2 minutes for the first 15 minutes after induction. PIH is defined as MAP below 65 mmHg and\u002For a decrease of 20% or more from baseline.",[384,27,385],"Hypotension on Induction","Anesthesia, General",[387,388,389,27,390,391,33],"Post-induction hypotension","EASIX","Endothelial Activation and Stress Index","Perioperative hemodynamics","Non-cardiac surgery","2026-06-08",{"date":367,"type":39},{"date":62,"type":21},{"date":396,"type":21},"2027-03-01",{"name":398,"class":46},"Konya City Hospital",{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":406,"targetDuration":408,"studyType":81,"phases":4,"briefSummary":409,"conditions":410,"keywords":415,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":425,"leadSponsor":427,"locationsCount":4},"100643721","evolution-of-physical-frailty-and-patient-reported-outcome-measures-in-kidney-transplant-candidates-a-mixed-methods-longitudinal-study-protocol-100643721","NCT07607041","Evolution of Physical Frailty and Patient-Reported Outcome Measures in Kidney Transplant Candidates: A Mixed-Methods Longitudinal Study Protocol","Longitudinal Tracking of Physical Frailty and Health-Related Quality of Life Through Patient-Reported Outcome Measures in Adult Candidates on the Kidney Transplant Waiting List","Inclusion Criteria:\n\n* Patients aged 18 years or older.\n* Diagnosed with Stage 5 chronic kidney disease (CKD).\n* Currently undergoing clinical evaluation for or actively listed on the deceased-donor kidney transplant waiting list at Hospital del Mar (Barcelona).\n* Cognitive and physical ability to understand and provide written informed consent.\n* Ability to use or have regular access to a digital device (smartphone or tablet) for electronic Patient-Reported Outcome Measures (ePROMs) completion.\n\nExclusion Criteria:\n\n* Severe cognitive impairment or active psychiatric disorders that prevent the reliable completion of questionnaires or physical tests.\n* Major physical disability that precludes the objective assessment of gait speed or handgrip strength (e.g., bilateral lower limb amputation or severe dominant hand deformity).\n* Acute medical illness requiring hospitalization at the time of enrolment.\n* Total language barrier that prevents understanding the study components or the qualitative interview.",{"count":407,"type":21},150,"24 Months","This study looks at how the physical and emotional health of people changes while they wait for a kidney transplant. Waiting for an organ can take a long time. During this period, some patients become \"frail.\" This means they lose strength and are at a higher risk for health problems.\n\nThe main goal is to follow these patients over time to better understand their needs. Researchers will use a mobile application to collect Patient-Reported Outcome Measures (PROMs) directly from patients about how they feel and their quality of life. The study will also include personal interviews to learn about the patients' experiences and any difficulties they face when using technology.\n\nThe results of this study will help to: • Identify early which patients are losing strength or health. • Improve the support that nurses provide during the transplant waiting period. • Make sure that digital health tools are easy for everyone to use.\n\nIn short, this work aims to help patients reach the day of their surgery in the best possible condition.",[411,27,412,413,414],"Kidney Failure, Chronic","Quality of Life","Kidney Transplantation","Patient Reported Outcome Measures",[413,416,358,417,418,419,420,421,422],"Waiting Lists","Digital Health","Longitudinal Studies","Mixed Methods Research","Hermeneutics","Patient-Centered Care","Technology Assessment, Biomedical",{"date":392,"type":39},{"date":64,"type":21},{"date":426,"type":21},"2028-07",{"name":428,"class":46},"Hospital del Mar",{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":435,"eligibilityCriteria":436,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":22,"phases":439,"briefSummary":440,"conditions":441,"keywords":448,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":47},"100626880","catheter-ablation-plus-laao-versus-anticoagulation-in-frail-elderly-patients-with-atrial-fibrillation-100626880","NCT07441382","Catheter Ablation Plus LAAO Versus Anticoagulation in Frail Elderly Patients With Atrial Fibrillation","Randomized Controlled Trial - Catheter Ablation Combined With Left Atrial Appendage Occlusion Versus Catheter Ablation Combined With Oral Anticoagulation for Elderly Frailty Patients With Atrial Fibrillation: Comparison of Efficacy and Safety","CLEAR-AF","Inclusion Criteria: (1) Age ≥ 75 years. (2) Confirmed diagnosis of non-valvular atrial fibrillation (paroxysmal or persistent). (3) CHA2DS2-VASc score ≥ 3 (high risk of stroke) . (4) Procedure-related criteria: Sequential Group: Participants who have received catheter ablation for non-valvular AF within 90 to 180 days prior to randomization. One-stop Group: Participants who are scheduled to undergo clinically indicated catheter ablation within 10 days after randomization. (5) Judged by the investigator to be able to tolerate the defined antithrombotic drug regimen. (6) Suitable to undergo Transesophageal Echocardiography (TEE) or Pulmonary Vein Computed Tomography (CT). (7) Able and willing to sign the written informed consent form. (8) Willing to return for all scheduled follow-up visits and examinations. Exclusion Criteria: (1) Presence of thrombus in the left atrium or left atrial appendage identified on preoperative imaging (echocardiogram, pulmonary vein CT, etc). (2) Major bleeding event (per ISTH definition) within 14 days prior to randomization. Participants must be excluded if clinical sequelae persist or if interventions for the bleeding source are planned\u002Fpending, regardless of the time elapsed since the event. (3) Requirement for long-term oral anticoagulation (OAC) for reasons other than stroke risk reduction in AF (e.g., underlying hypercoagulable state) that would prevent OAC discontinuation post-device implantation. (4) Any cardiac or major non-cardiac intervention\u002Fsurgery (excluding AF ablation and cardioversion) performed within 30 days prior to, or scheduled within 60 days after randomization. This includes but is not limited to Percutaneous Coronary Intervention (PCI) or other cardiac ablations. (5) Life expectancy \\\u003C 2 years, malignancy, infectious endocarditis, uncontrolled infection, or physiological evidence of cardiac tamponade. (6) Clinical Frailty Scale (CFS) score of 1-3 (not frail) or 7-9 (severely frail\u002Fterminally ill). (7) Deemed unsuitable for long-term anticoagulation and\u002For antiplatelet therapy by the investigator due to bleeding risk, allergies, or other reasons. (8) Current participation in another clinical trial that interferes with this study, excluding mandatory government or purely observational registries. (9) Stroke or transient ischemic attack (TIA) within 60 days prior to randomization. (10) Documented myocardial infarction (NSTEMI or STEMI) within 90 days prior to randomization, regardless of intervention. (11) History of atrial septal defect (ASD) repair or presence of an ASD\u002FPatent Foramen Ovale (PFO) occluder. (12) Presence of a mechanical prosthetic valve in any position. (13) Participants of childbearing potential who are pregnant or planning pregnancy during the study period. (14) Medical or anatomical contraindications to percutaneous catheter-based interventions. (15) Documented NYHA Class IV heart failure. (16) History of surgical left atrial appendage (LAA) closure.\n\nTransthoracic Echocardiography (TTE) Specific Exclusions: (1) Low LVEF: Left ventricular ejection fraction (LVEF) \\\u003C 30%. (2) Presence of pericardial effusion with a circumferential echo-free space \\> 5mm. (3) Presence of high-risk PFO associated with an atrial septal aneurysm (ASA) with an excursion or length \\> 15mm. (4) Presence of high-risk PFO with a large shunt (defined as appearance of microbubbles within 3 cardiac cycles and\u002For a substantial count of microbubbles). (5) Presence of moderate or severe mitral stenosis (mitral valve area \\\u003C 1.5 cm2).",{"count":438,"type":21},200,[24],"Atrial fibrillation (AF) is the most common arrhythmia, significantly increasing the risk of stroke, heart failure, hospitalization and death in patients. Studies have shown that standardized anticoagulation can effectively reduce the risk of stroke by 64% and the risk of death by 26% in AF patients. Therefore, both European and American guidelines recommend standardized oral anticoagulation (OAC) as an important treatment strategy for stroke prevention in AF patients. However, the use of OAC may also increase the risk of bleeding in patients. Results from large AF anticoagulation randomized trials show that the annual risk of anticoagulation-related bleeding mortality is 2% to 3%. Therefore, according to the guidelines recommendations, assessing the bleeding risk is necessary in patients with anticoagulant indications.\n\nPercutaneous left atrial appendage occlusion (LAAO) is a device-based therapy that aims to prevent ischemic stroke in patients with AF. For patients with contraindications to long-term anticoagulation therapy, LAAO can be considered as an alternative strategy to oral anticoagulation (Class II B recommendation) to prevent ischemic stroke and thromboembolism. Multiple studies have shown that LAAO is non-inferior to warfarin and novel oral anticoagulants in stroke prevention for non-valvular AF patients. Age is not only a risk factor for stroke but also an important risk factor for bleeding. In the elderly population, especially those with frailty, the risk factors for both stroke and bleeding are often increased. Currently, there is insufficient evidence to support the use of OAC in frail elderly patients with relative anticoagulant contraindications. Therefore, elderly AF patients may be one of the potential beneficiary groups for LAAO. However, most previous clinical studies on LAAO were based on small sample sizes to analyze their safety and efficacy, and clinical data on the safety and efficacy of LAAO in this high-risk population of elderly AF patients are still limited. To address this, the study aims to conduct a multicenter randomized controlled trial to compare the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients with high bleeding risk, filling the gap in this research area.\n\nTo address these limitations, this multicenter randomized controlled trial is designed to evaluate the efficacy and safety of catheter ablation combined with LAAO versus catheter ablation combined with OAC in elderly AF patients at high risk for bleeding. The primary objective of the study is to compare the 12-month incidence and time-to-occurrence of the composite clinical endpoint. This endpoint includes stroke\u002FTIA, systemic embolism, ISTH-defined major bleeding. By establishing these metrics within the first year, the study aims to fill the current void in clinical evidence and provide a standardized treatment strategy for high-risk elderly patients. In addition to the primary endpoints, the study will conduct a comprehensive long-term evaluation extending to 24 months post-procedure to assess the durability of both treatment strategies. Secondary objectives include the assessment of perioperative safety, specifically focusing on serious intraoperative complications and major adverse events occurring within the first seven days after the LAAO procedure. The trial will also measure long-term rhythm control by tracking the rate of freedom from AF recurrence at the one-year and two-year marks. Furthermore, the study seeks to verify the hypothesized superiority of the ablation-plus-LAAO strategy in reducing the specific burden of anticoagulation-related major bleeding and stroke.\n\nBeyond clinical safety and efficacy, the trial will analyze the practical aspects of the two interventions, including procedural success rates, operation duration, fluoroscopy time, and the total duration of hospitalization. A critical component of the research involves identifying specific risk factors associated with complications, with a specialized focus on how frailty scores influence procedural tolerance and long-term prognosis. The study will further explore how different types of AF respond to the LAAO strategy and assess the impact of each treatment on non-major bleeding events. Ultimately, the trial aims to determine which strategy offers a superior improvement in the overall quality of life for elderly patients, thereby optimizing future clinical guidelines.",[442,443,444,27,445,446,447],"Atrial Fibrillation (AF)","Stroke","Hemorrhage","Atrial Appendage","Catheter Ablation","Anticoagulants",[449,450,443,444,447,27,451,452,446],"Atrial Fibrillation","Left Atrial Appendage Closure","Aged","Randomized Controlled Trial",{"date":392,"type":39},{"date":455,"type":39},"2026-03-24",{"date":457,"type":21},"2028-03-01",{"name":459,"class":46},"Guangdong Provincial People's Hospital",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":22,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":475,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":479,"locationsCount":481},"100495034","assisted-ambulation-to-improve-health-outcomes-for-older-medical-inpatients-100495034","NCT05725928","Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients","Randomized Trial of Assisted Ambulation to Improve Health Outcomes for Older Medical Inpatients","Inclusion Criteria:\n\nParticipants must meet all of the inclusion criteria listed below to participate in this study:\n\n1. ≥65 years of age\n2. Admitted to a medical service\n3. Complete history and physical examination on file\n4. 6-Clicks score of 16-23\n5. Insurance with Traditional Medicare or Medicare Advantage\n\nExclusion Criteria:\n\nAny patient meeting any of the exclusion criteria listed below at baseline will be excluded from study participation:\n\n1. Significant language barrier that requires a translator (other than Spanish at Baystate site only)\n2. Discharge planned for that day or the following day\n3. Observation status\n4. Surgical procedure planned\n5. Patients diagnosed with unstable angina or other medical conditions precluding participation in exercise\u002Fambulation\n6. Permanent residence in a skilled nursing facility\n7. Comfort care measures only\n8. \\>48 hours since admission\n9. Active infection with COVID-19\n10. Other active infection requiring contact or droplet precautions\n11. Order for bedrest",{"count":468,"type":21},3000,[24],"The investigator proposes to conduct a randomized trial of supervised ambulation delivered by mobility technician (MT) up to three times daily, including weekends, to hospitalized medical patients. The aims of the study are to compare the short and intermediate-term outcomes of patients randomized to the intervention versus those patients randomized to receive usual care, to identify patients who are most likely to benefit from the intervention and to assess whether the intervention increases or decreases overall costs of an episode of care, including the cost of the MTs, the index hospitalization and the first 30 days post enrollment.",[472,27,473,474],"Mobility Limitation","Hospital Acquired Condition","Weakness, Muscle",{"date":392,"type":39},{"date":477,"type":39},"2023-05-15",{"date":121,"type":21},{"name":480,"class":46},"The Cleveland Clinic",5,{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":489,"enrollmentInfo":490,"targetDuration":4,"studyType":22,"phases":491,"briefSummary":492,"conditions":493,"keywords":496,"overallStatus":207,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":47},"100642856","silkworm-pupa-powder-improves-alzheimers-disease-100642856","NCT07638449","Silkworm Pupa Powder Improves Alzheimer's Disease","A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients","Inclusion Criteria:\n\n* Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.\n* Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):\n* Aβ positivity: Plasma Aβ42\u002F40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).\n* Tau positivity: Plasma p-tau217 ≥2.5 pg\u002FmL (or CSF p-tau181\u002FAβ42 ratio ≥0.02).\n* Age 50 to 90 years (inclusive), male or female, with at least a primary school education.\n* Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.\n* Hachinski Ischemia Scale (HIS) total score ≤4.\n* Geriatric Depression Scale-15 (GDS-15) total score ≤4.\n* Neuroimaging evidence: Screening CT\u002FMRI showing age-related brain changes or cerebral atrophy.\n* Participant has a stable and reliable caregiver, as confirmed by the investigator.\n* Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants must agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.\n\nExclusion Criteria:\n\n* Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.\n* Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.\n* Abnormally low folate and\u002For vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.\n* Comorbid psychiatric disorders.\n* Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.\n* Intolerance or allergy to the study medication (silkworm pupa powder).\n* Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.\n* Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.\n* Geriatric Depression Scale-15 (GDS-15) score \\>4 at screening.\n* Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.\n* Administration of any new chemical entity in an AD clinical study within 6 months prior to screening.\n* Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures or safety.\n* Participation in a clinical study involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening.\n* Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapy and any BACE inhibitor therapy).\n* Any inadequately controlled immune disorder, or immune disease requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.\n* Inadequately controlled bleeding disorders (including platelet count \\\u003C50,000 or INR \\>1.5 for participants not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have their anticoagulation status optimized and receive a stable dose within 4 weeks prior to screening. Participants receiving anticoagulant therapy must not participate in cerebrospinal fluid (CSF) assessments.\n* Participation in another concurrent silkworm pupa powder intervention study conducted at the same study center.","90 Years",{"count":80,"type":21},[24],"The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:\n\n* Does silkworm pupa powder improve cognitive function and daily living abilities?\n* Does silkworm pupa powder improve nutritional status and frailty?\n* What medical problems do participants have when taking silkworm pupa powder?\n\nResearchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.\n\nParticipants will:\n\n* Take silkworm pupa powder every day for 12 weeks\n* Visit the clinic once every 4 weeks for checkups and tests\n* Use an electronic punch-card system daily and report any symptoms",[494,197,495,27],"Alzheimer Disease","Asthenia",[497,498,499,500,501],"Silkworm Pupa Powder","Nutritional Status","Frailty State","Cognitive Function","Dietary Supplement","2026-06-04",{"date":504,"type":39},"2026-06-10",{"date":506,"type":21},"2026-06-01",{"date":508,"type":21},"2027-12-31",{"name":510,"class":46},"Zhejiang Provincial Tongde Hospital",{"id":512,"slug":513,"hasResults":12,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":103,"minAge":132,"maxAge":4,"enrollmentInfo":518,"targetDuration":4,"studyType":22,"phases":520,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":47},"100467293","prehabilitation-for-ovarian-cancer-patients-100467293","NCT05364879","Prehabilitation for Ovarian Cancer Patients","The Impact of Prehabilitation Exercise on Frailty and Treatment Outcomes in Ovarian Cancer Patients","Inclusion Criteria:\n\n* 18 years or older\n* Have a confirmed diagnosis of stage III or IV ovarian cancer\n* Scheduled to receive cytoreductive surgery as part of their treatment plan\n* Must have a minimum of 4-weeks between the time of study enrollment and scheduled surgery\n* Be able to attend in-person and\u002For virtual exercise sessions\n* Be fluent in English\n* Have oncologist approval\n\nExclusion Criteria:\n\n* Have already completed surgery\n* Unstable cardiac or respiratory disease, injury or any other co-morbid disease that may make it unsafe for participants to exercise\n* Significant cognitive impairment (e.g., do not have the capacity to consent, unable to follow exercise instructions)",{"count":519,"type":21},108,[24],"Individuals with ovarian cancer have very poor survival rates. This is because the cancer is not usually detected until it has reached advanced stages. How long an individual survives also is determined by the cancer treatment they receive. Although there are best treatment practices to improve survival, some women have other conditions that limit treatment options. One such condition seen in as many as 50% of women with advanced ovarian cancer is frailty (an age-related decline in function and health). This is a major concern as doctors will often have to change how the cancer is treated based on the patient being frail. For example, patients living with frailty are less likely to have their full tumor removed during surgery. They are also more likely to have complications with surgery, stay in the hospital longer, and recover less well from surgery overall. Patients living with frailty also are more likely to experience delays in their chemotherapy starting, receive lower doses of chemotherapy and\u002For receive fewer cycles of chemotherapy. These changes in treatment may decrease how long a patient survives after diagnosis. Thus, research is needed to explore strategies to decrease frailty in patients who require treatment for advanced ovarian cancer. An option gaining more attention is physical exercise (e.g. walking, repeatedly rising from a chair). Exercise performed before surgery, which is called prehabilitation, can improve how well a patient recovers after surgery and increase how long they survive. Research has shown that prehabilitation is very beneficial for patients undergoing surgery for heart disease. However, it is not clear whether prehabilitation works for those with advanced ovarian cancer that are going to have surgery. Therefore, the investigators want to explore how a 4+ week exercise program performed while waiting for surgery for advanced ovarian cancer changes frailty and how a patient recovers after surgery. The investigators will specifically look whether the exercise program: 1) reduces how frail a patient is before surgery; 2) improves how well the patient recovers after surgery; and 3) affects the patient's chemotherapy treatment plan. This study will provide important information about the ability of prehabilitation exercise to improve surgical and treatment outcomes in women with advanced ovarian cancer. Overall, it is believed that exercise has the potential to improve the survival of advanced ovarian cancer patients.",[523,524,27,525,526,527,528],"Prehabilitation","Exercise","Ovarian Cancer","Surgical Complication","Treatment Outcomes","Enhanced Recovery After Surgery","2026-05-28",{"date":506,"type":39},{"date":532,"type":39},"2023-01-03",{"date":534,"type":21},"2027-08-31",{"name":536,"class":46},"Nova Scotia Health Authority",{"id":538,"slug":539,"hasResults":12,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":4,"eligibilityCriteria":543,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":542,"conditions":545,"keywords":547,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":553,"startDateStruct":555,"completionDateStruct":557,"leadSponsor":558,"locationsCount":47},"100629522","ultrasound-nutritional-status-and-outcomes-in-surgical-icu-100629522","NCT07475767","Ultrasound, Nutritional Status, and Outcomes in Surgical ICU","Ultrasound Indicators of Nutritional Status and Treatment Outcomes in Surgical Patients in the Intensive Care Unit","Inclusion Criteria:\n\n* postoperative intensive care\n\nExclusion Criteria:\n\n* surgery of the right leg\n* paraplegia, tetraplegia\n* refusal of the patient\u002Fguardian to participate in the research (informed consent not signed)",{"count":57,"type":21},[498,546,27],"Muscle Thickness of the Quadriceps Femoris",[498,548,549,550,551],"Risk Assessment","Ultrasonography","Intensive Care Units","Postoperative Care","2026-05-27",{"date":554,"type":39},"2026-05-29",{"date":556,"type":39},"2026-02-01",{"date":64,"type":21},{"name":559,"class":46},"Osijek University Hospital",{"id":561,"slug":562,"hasResults":12,"nctId":563,"briefTitle":564,"officialTitle":565,"acronym":4,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":17,"minAge":224,"maxAge":4,"enrollmentInfo":567,"targetDuration":4,"studyType":22,"phases":569,"briefSummary":570,"conditions":571,"keywords":575,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":552,"lastUpdatePostDateStruct":579,"startDateStruct":580,"completionDateStruct":582,"leadSponsor":584,"locationsCount":47},"100552157","the-impact-of-geriatric-assessment-on-the-treatment-plan-of-elderly-patients-with-t2dm-100552157","NCT06469437","The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With T2DM","The Impact of Geriatric Assessment on the Treatment Plan of Elderly Patients With Type 2 Diabetes Mellitus: a Randomized Clinical Trial.","Inclusion Criteria:\n\n* Age 60 years or older\n* Diagnostic of type 2 diabetes mellitus according to American Diabetes Association criteria\n* Patients under follow-up in a specialized endocrinology outpatient clinic\n* Patients who have a glycated hemoglobin measurement of up to three months\n\nExclusion Criteria:\n\n* Lack of consent for research participation from the patient or the physician\n* Patients classified as Clinical Frailty Scale 9.",{"count":568,"type":21},220,[24],"Introduction: With the aging of the world population and the increasing incidence of type 2 diabetes mellitus (T2DM) with age, the number of elderly individuals living with diabetes has been considerably rising. It is known that uncontrolled T2DM negatively impacts various health outcomes, including geriatric outcomes such as sarcopenia, frailty, immobility, incontinence, and infections. Current medical literature fails to establish appropriate glycemic targets for different elderly profiles. Although guidelines emphasize the need to individualize targets, there is no concise tool to identify which individuals benefit from each therapeutic approach. Data suggest that frailty is the best predictor of negative outcomes in elderly patients living with T2DM. The Clinical Frailty Scale (CFS) and the 10-minute Targeted Geriatric Assessment (TaGA-10) are validated tools for prognosis in elderly patients and for identifying frail elderly individuals.\n\nMethods: Randomized controlled trial. Elderly individuals diagnosed with T2DM at a tertiary care outpatient clinic will be included. All enrolled patients will undergo geriatric assessment using CFS, TaGA-10, and Charlson Comorbidity Index. Patients will be randomized into usual care and intervention groups, and the intervention involves providing the geriatric assessment to the care team to support their decisions. The adequacy of the therapeutic approach will be measured in one week by reviewing the consult record or interviewing the physician. The clinical impact on the frequency of hypoglycemia, falls, infections, hospitalizations, and mortality will be evaluated at 3 and 6 months by telephone interviews.\n\nDiscussion: Current guidelines recommend using age, comorbidities, cognitive, and functional status to individualize therapeutic targets in elderly patients with T2DM; however, it is possible that these variables alone may not be sufficient to classify all elderly individuals in their complexity adequately. A tool with such power and easy to use in clinical practice is necessary.",[572,573,27,574],"Type2diabetes","Frail Elderly Syndrome","Geriatric Assessment",[576,27,577,578],"Type 2 diabetes","Geriatric assessement","Glycated hemoglobin",{"date":554,"type":39},{"date":581,"type":39},"2024-07-05",{"date":583,"type":21},"2028-12-31",{"name":585,"class":46},"Hospital de Clinicas de Porto Alegre",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":591,"acronym":592,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":594,"targetDuration":4,"studyType":22,"phases":596,"briefSummary":597,"conditions":598,"keywords":600,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":608,"lastUpdatePostDateStruct":609,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":614,"locationsCount":47},"100569363","investigating-the-combined-effects-of-protein-blueberries-and-exercise-on-cardiovascular-health-and-frailty-in-older-nova-scotians-100569363","NCT06693271","Investigating the Combined Effects of Protein, Blueberries, and Exercise on Cardiovascular Health and Frailty in Older Nova Scotians","The STudy on bluebeRries, prOteiN, and Exercise for improvinG Frailty and Cardiovascular Disease (STRONG)","STRONG","Inclusion Criteria:\n\n* Must be 65 years of age or above\n* Must be willing to participate in a low to moderate exercise program\n\nExclusion Criteria:\n\n* Medical and cognitive conditions that prevent participation in the intervention\n* Allergies and or dislike of blueberries and\u002For protein powder",{"count":595,"type":21},240,[24],"Cardiovascular diseases (CVD) are a leading cause of morbidity and mortality worldwide. While CVDs are predominantly diseases of aging, age itself does not predict CVD risk; people age at different rates. Frailty is a state of accelerated aging that increases the risk of adverse health outcomes. Frail people are at higher risk of developing CVDs, experiencing complications, and dying from these diseases than fit people of the same age. Indeed, frailty predicts the likelihood of developing CVD independently of traditional risk factors for CVD. It is known that older women are frailer than men and tend to express CVDs differently than men, but whether relationships between frailty and CVD are sex specific is unclear. It is possible that shared pathophysiological mechanisms such as chronic inflammation may help explain links between CVD and frailty. Importantly, the degree of frailty can be modified by lifestyle interventions. For example, sedentary lifestyles, food insecurity, and suboptimal dietary habits can exacerbate frailty whereas diet and exercise interventions can attenuate frailty.\n\nThe investigators propose that a comprehensive health strategy targeting diet and physical activity to reduce frailty will reduce the risk of cardiovascular disease (CVD), thereby promoting healthy aging. Engaging in physical activity (e.g. exercise) helps improve aerobic fitness, increase muscle mass, promote cardiac regeneration, enhance metabolic function, regulate blood pressure, improve insulin sensitivity, reduce inflammation (a key frailty mechanism), and lessen frailty. High-quality dietary protein is essential to maintain muscle mass\u002Ffunction, preserve mobility, attenuate inflammation, and reduce frailty. Packed with antioxidants such as anthocyanins and flavonoids, with high levels of fiber, vitamins, and minerals, blueberries, a local Nova Scotian food, can help lower blood pressure, improve blood vessel function, reduce inflammation, and help the body utilize dietary protein. These are critical aspects of a strong heart and healthy aging. To date, many frailty intervention studies have been limited by small sample sizes, underrepresentation of women, and\u002For by testing individual lifestyle modifications rather than synergistic effects; additionally, none have investigated how reducing frailty impacts cardiovascular outcomes. Our goal is to determine if a year-long multidomain intervention of protein, blueberries, and exercise reduces frailty and cardiovascular disease risk in older at-risk Nova Scotians of both sexes.",[599,27],"Cardiovascular Disease",[599,27,601,524,602,603,604,605,606,607],"Blueberries","Protein","Obesity","Hypertension","Hyperlipidemia","Sedentary Lifestyle","Older Adults","2026-05-19",{"date":610,"type":39},"2026-05-20",{"date":612,"type":39},"2025-12-15",{"date":583,"type":21},{"name":536,"class":46},{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":12,"sex":17,"minAge":55,"maxAge":622,"enrollmentInfo":623,"targetDuration":4,"studyType":22,"phases":624,"briefSummary":626,"conditions":627,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":631,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":638},"100558714","phase-2-tesamorelin-as-an-adjunct-to-exercise-for-improving-physical-function-in-hiv-100558714","NCT06554717","Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV","TRIUMPH","Inclusion Criteria:\n\n1. Men and women, 50-80 years old\n2. Documented HIV infection on suppressive antiretroviral therapy for at least 1 year with HIV-1 RNA \\\u003C200 copies\u002FmL and CD4+ T cell count \\>200\u002FµL 3\n3. Sedentary lifestyle, defined as self-reported physical activity that breaks a sweat \\\u003C3 days\u002Fweek with no regular resistance exercise in the past 3 months\n4. ≥1 Fried frailty criterion (weakness, slow gait speed, exhaustion, decreased physical activity, or unintentional weight loss as defined by specific thresholds)\n5. Excess abdominal adiposity as indicated by at least one of the following elevated anthropometric measures assessed at Screen: (1) waist circumference ≥102 cm in non-Asian males (≥90 cm in Asian males) or ≥88 cm in non-Asian females (≥80 cm in Asian females); (2) waist-to-hip ratio ≥0.9 in males or ≥0.85 in females; (3) waist-to-height ratio ≥0.5 in males and females\n6. Normal mammogram within 2 years (females ≤74 years old) or prostate specific antigen \\\u003C4 ng\u002FmL (males ≤70 years old) per U.S. Preventive Services Task Force (USPSTF) age-appropriate cancer screening guidelines\n7. For females, postmenopausal defined as no menses for ≥12 months and anti-müllerian hormone (AMH) \\\u003C20 pg\u002FmL or history of bilateral oophorectomy at least 3 months ago\n8. Provider approval to participate\n\nExclusion Criteria:\n\n1. Use of tesamorelin or other growth hormone (GH)-based therapy within 6 months\n2. Insulin-like growth factor 1 (IGF-1) z-score \\>2.0\n3. HbA1c \\>8%\n4. Active or suspected malignancy (with the exception of non-melanoma skin cancer) within 24 months\n5. Supraphysiologic testosterone or corticosteroid exposure, or change in exogenous testosterone or corticosteroid dose within 3 months\n6. Change in glucose-lowering medication (e.g., glucagon-like peptide-1 receptor agonists) within 3 months\n7. Active or unstable coronary artery disease, chest pain suspicious for angina, or serious arrythmia\n8. History of hypopituitarism, head irradiation, or other conditions known to affect the GH\u002FIGF-1 axis\n9. Known hypersensitivity to tesamorelin or mannitol\n10. Acute or chronic illness judged by the investigator to represent a contraindication to study participation","80 Years",{"count":80,"type":21},[625],"PHASE2","People with HIV experience earlier impairments in physical function compared to people in the general population. They also exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterized by reduced activity, fatigue, slowness, weakness, and weight loss. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long-term.\n\nThe goal of this clinical trial is to learn whether the medication tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise. Tesamorelin is a growth hormone-releasing hormone analogue that is FDA-approved to treat abdominal fat accumulation in people with HIV. While tesamorelin has also been shown to increase muscle mass and improve measures of muscle health, its effects on physical performance and muscle strength have not yet been evaluated.\n\nDuring a 24-week intervention phase, half of participants will be randomly assigned to receive tesamorelin and half of participants will be randomly assigned to receive placebo (a look-alike substance that contains no drug). All participants also will engage in a home-based exercise intervention supervised by an exercise coach. During a subsequent 24-week extension phase, individuals will be monitored off study drug and supervised exercise, and be encouraged to continue to exercise independently.\n\nThe investigators will investigate effects of tesamorelin on physical function, muscle mass and quality, quality of life, and exercise adherence and self-efficacy. They also will evaluate whether effects of tesamorelin are maintained following treatment cessation. This study may identify an important strategy to improve how individuals aging with HIV function and feel with potential applications to other patient populations.",[628,27,629,630,144],"HIV-1-infection","Impaired Physical Function","Abdominal Obesity",{"date":608,"type":39},{"date":633,"type":39},"2025-07-10",{"date":635,"type":21},"2028-12-01",{"name":637,"class":46},"Massachusetts General Hospital",2,{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":643,"acronym":4,"eligibilityCriteria":644,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":622,"enrollmentInfo":645,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":646,"conditions":647,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":651,"lastUpdatePostDateStruct":652,"startDateStruct":653,"completionDateStruct":654,"leadSponsor":656,"locationsCount":47},"100638839","effect-of-sarcopenia-and-frailty-on-rocuronium-pharmacodynamics-in-geriatric-patients-100638839","NCT07580144","Effect of Sarcopenia and Frailty on Rocuronium Pharmacodynamics in Geriatric Patients","Inclusion Criteria:\n\n* Scheduled to undergo elective surgery under general anesthesia requiring endotracheal intubation\n* Planned use of rocuronium for neuromuscular blockade\n* Quantitative neuromuscular monitoring planned during anesthesia\n* American Society of Anesthesiologists physical status I-III\n* Ability to provide written informed consent\n* Completion of preoperative frailty and sarcopenia assessment\n\nExclusion Criteria:\n\n* Emergency surgery\n* Known neuromuscular disease\n* History of allergy or contraindication to rocuronium, sugammadex\n* Severe hepatic insufficiency\n* Severe renal insufficiency\n* Use of drugs known to significantly affect neuromuscular transmission\n* Preoperative mechanical ventilation or intensive care unit admission\n* Inability to perform a frailty or sarcopenia assessment\n* Patients in whom quantitative neuromuscular monitoring cannot be properly performed\n* Refusal to participate in the study",{"count":80,"type":21},"This prospective observational study aims to evaluate whether sarcopenia and frailty affect the pharmacodynamic profile of rocuronium in geriatric patients undergoing elective surgery under general anesthesia.",[197,27,648,649,650],"Neuromuscular Blockade","Rocuronium","Pharmacodynamics","2026-05-13",{"date":119,"type":39},{"date":651,"type":39},{"date":655,"type":21},"2026-08-05",{"name":657,"class":46},"Konya Meram State Hospital",{"id":659,"slug":660,"hasResults":12,"nctId":661,"briefTitle":662,"officialTitle":663,"acronym":664,"eligibilityCriteria":665,"healthyVolunteers":12,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":666,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":667,"conditions":668,"keywords":671,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":47},"100638191","cally-index-frailty-and-sofa-2-for-mortality-prediction-in-geriatric-icu-patients-100638191","NCT07579728","CALLY Index, Frailty and SOFA-2 for Mortality Prediction in Geriatric ICU Patients","Prognostic Value of CALLY Index, Frailty and SOFA-2 Score for Mortality in Geriatric Intensive Care Patients: A Prospective Cohort Study","CALLY-FS","Inclusion Criteria:\n\n* Age ≥65 years\n* Admission to the intensive care unit\n* Availability of required clinical and laboratory data within the first 24 hours of ICU admission\n\nExclusion Criteria:\n\n* Death within the first 24 hours after ICU admission\n* Missing key clinical or laboratory data\n* Terminal malignancy receiving palliative care",{"count":80,"type":21},"This study aims to evaluate the prognostic value of the C-reactive protein-albumin-lymphocyte (CALLY) index, Clinical Frailty Scale (CFS), and SOFA-2 score in predicting mortality among geriatric intensive care unit (ICU) patients.\n\nThe primary outcome is ICU mortality. Secondary outcomes include 28-day mortality, ICU length of stay, duration of mechanical ventilation, need for renal replacement therapy, and vasopressor requirement.\n\nThe study also investigates whether the combined use of these parameters improves predictive performance compared to conventional scoring systems such as APACHE II.",[669,27,670],"Critical Illness","Intensive Care Unit (ICU)",[672,203,673,674,675],"CALLY index","SOFA-2 score","ICU mortality","Geriatric patients","2026-05-06",{"date":678,"type":39},"2026-05-12",{"date":680,"type":39},"2026-04-30",{"date":682,"type":21},"2026-07-10",{"name":684,"class":46},"Istanbul University - Cerrahpasa",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":690,"acronym":4,"eligibilityCriteria":691,"healthyVolunteers":12,"sex":17,"minAge":224,"maxAge":4,"enrollmentInfo":692,"targetDuration":4,"studyType":22,"phases":694,"briefSummary":695,"conditions":696,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":699,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":707},"100526980","twice-vs-thrice-weekly-incident-hemodialysis-in-elderly-patients-100526980","NCT06141798","Twice vs Thrice Weekly Incident Hemodialysis in Elderly Patients","A Pragmatic Randomized Clinical Trial: Twice-weekly vs Thrice-weekly Incident hemoDialysis in Elderly Patients","Inclusion Criteria:\n\n* Age ≥60 years\n* Clinical diagnosis of end stage kidney disease\n* Starting maintenance hemodialysis within one month\n* 24-hour urine output ≥ 500 ml at randomization\n* Sufficient understanding of the study procedures and requirements.\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction \\\u003C 40%)\n* Liver cirrhosis\n* Current treatment for an active malignancy or active infection\n* Onability or refusal to provide written informed consent\n* enrollment in another clinical trial.",{"count":693,"type":21},428,[24],"As Korea is becoming a super-aged society, the number of elderly patients with end-stage kidney disease (ESKD) is expected to increase rapidly. Therefore, the burden on Korean society will also increase.\n\nThrice-weekly hemodialysis is standard for renal replacement therapy. However, this regimen has not been validated for elderly ESKD patients with residual renal function. Elderly patients can have multiple comorbidities such as hypertension, diabetes, cardiovascular disease, and impaired physical activity. Frequent hemodialysis could provoke falls, hypotension, and cognitive impairment. Previous reports have suggested the potential benefit of twice-weekly hemodialysis with incremental increases in frequency when residual renal function decreases. In addition, twice-weekly hemodialysis decreases hospitalization rates in frail patients.\n\nTherefore, the investigators hypothesized initiating renal replacement therapy with twice-weekly hemodialysis decreases the hopsitalizatoin rates compared with conventional thrice-weekly hemodialysis in elderly ESRD patients with residual renal function. This study is a pragmatic randomized clinical trial, multicenter study. Study subjects are incident ESRD patients (\\>= 60 years old, n=428) with residual urine volume ( \\> 500 mL\u002Fday) and follow up up to 2 years. Twice-weekly hemodialysis could be incremented according to clinical situations such as volume overload, hyperkalemia and uremic symptom. Primary outcome of this study is hospitalization rate during follow-up. Secondary outcomes include dialysis related hospitalization rate, the length of hospital stay, complication of dialysis,mortality rate and assessments of quality of life, frailty, and cost-utility.",[697,698,27,412],"Age Problem","Dialysis; Complications",{"date":700,"type":39},"2026-05-11",{"date":702,"type":39},"2021-11-23",{"date":704,"type":21},"2026-05-31",{"name":706,"class":46},"Soonchunhyang University Hospital",7,{"id":709,"slug":710,"hasResults":12,"nctId":711,"briefTitle":712,"officialTitle":712,"acronym":713,"eligibilityCriteria":714,"healthyVolunteers":12,"sex":17,"minAge":132,"maxAge":78,"enrollmentInfo":715,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":716,"conditions":717,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":719,"lastUpdatePostDateStruct":720,"startDateStruct":722,"completionDateStruct":724,"leadSponsor":726,"locationsCount":481},"100510617","evaluation-of-the-clinical-frailty-scale-cfs-as-a-risk-factor-of-mortality-in-adult-patients-65-years-of-age-admitted-to-intensive-care-for-septic-shock-100510617","NCT05928767","Evaluation of the Clinical Frailty Scale (CFS) as a Risk Factor of Mortality in Adult Patients ≤65 Years of Age Admitted to Intensive Care for Septic Shock.","Woodstock","Inclusion Criteria:\n\n* Patients aged ≥18 years and ≤ 65 years\n* Patient admitted to intensive care - resuscitation\n* Patient admitted for suspected or documented type 3 sepsis\n* Presence of vasopressor amines to maintain MAP \\> 65mmHg despite filling\n* Lactatemia ≥ 2 mmol\u002FL on admission.\n\nExclusion Criteria:\n\n* Patient moribund on admission\n* Patients with severe pre-existing dementia and\u002For cognitive decline, suffering from severe neurodegenerative diseases that prevent the patient from living independently at baseline, including mental illness requiring institutionalisation, including acquired or congenital mental retardation, etc.\n* Pregnant women or women in labour\n* Patients under guardianship or curatorship\n* Patients deprived of their liberty\n* Patient and\u002For family unable to speak or understand French.",{"count":438,"type":21},"The aim of the study is to demonstrate that \"frail\" patients, defined as having a CFS score greater than or equal to 5, and \"severely\" frail patients, defined as having a CFS score between \\[6-7\\] as defined by Bagshaw et al (14), constitute an independent risk factor (RF) for mortality.\n\nIn the same way, as an exploratory study, we will try to find out whether clinical frailty constitutes a risk factor for extending the length of hospital stay, the risk of short\u002Fmedium-term readmission, as has already been demonstrated for patients admitted to intensive care from all causes (15), or for impaired quality of life.\n\nThe objective is to have a better understanding of the implications and outcomes associated with pre-hospital frailty in young critically ill patients.\n\nThis analysis will also help to clarify prognoses and contribute to better decision-making on the intensity and proportionality of care, as well as providing better information and helping to manage the expectations of patients and their families in terms of survival prognosis and subsequent quality of life.",[27,718],"Septic Shock","2026-05-05",{"date":721,"type":39},"2026-05-08",{"date":723,"type":39},"2023-08-21",{"date":725,"type":21},"2026-11",{"name":727,"class":46},"Centre Hospitalier de Lens"]